Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data GUIDED THERAPEUTICS INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0.24
0.06
0.04
0.1
0.08
0.01
0.1
0.01
0.77
Cost of revenue
0.49
0.53
0.09
0.07
-0.04
0.06
0.08
0.06
0.01
0.2
Gross profit
0.11
-0.29
-0.03
-0.03
0.14
0.02
-0.07
0.04
0
0.57
Research and development
0.73
0.33
0.24
0.12
0.14
0.07
0.08
0.23
0.53
0.47
Selling and marketing
0.39
0.25
0.2
0.09
0.14
0.14
0.18
0.27
0.29
0.17
General and administrative
2.81
2.26
1.08
0.69
0.91
2.17
3.01
3
1.3
2.31
Operating expenses
3.93
2.84
1.52
0.9
1.2
2.38
3.27
3.49
2.11
2.94
Operating income
-3.82
-3.12
-1.55
-0.94
-1.05
-2.36
-3.33
-3.46
-2.11
-2.37
Interest expense
1.9
1.11
1.76
1.41
1.06
1.15
0.58
0.28
0.38
0.62
Interest income
0
0
Other non-operating income
-0.15
-7.58
2.56
-0.98
0.77
0.29
-1.01
-0.03
-0.31
-0.82
Pre-tax income
-3.97
-10.7
1.02
-1.92
-0.28
-2.07
-4.34
-3.49
-2.42
-3.2
Income tax
0
0
0
0
0
0
0
0
0
0
Net income
-3.97
-10.7
1.02
-1.92
-0.28
-2.07
-4.34
-3.49
-2.42
-3.2
EBITDA
-2.6
-2.91
-1.52
-0.92
-1.05
-2.36
-3.33
-3.45
-2.1
-2.36
EPS, basic
-24.62
997.64
1.95
-0.58
-0.04
-0.18
-0.15
-0.07
-0.05
-0.04
EPS, diluted
-24.62
0.00
0.01
-0.58
-0.04
-0.18
-0.15
-0.07
-0.05
-0.04
Shares, basic (weighted)
0
0
0
0
10.8
13.4
32.5
57.3
78.4
Shares, diluted (weighted)
0
0
0.07
0
0.01
13.4
32.5
51.1
57.3
78.4
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.01
0
0
0.9
0.18
0.64
2.31
0.59
0.39
0.06
Receivables
0.05
0.01
0.01
0
0
Inventory
0.77
0.18
0.11
0.05
0.61
0.57
0.55
0.63
0.63
0.45
Other current assets
0.26
0.11
0.07
0.07
0.09
0.38
0.14
0.16
0.17
0.09
Total current assets
1.05
0.3
0.2
1.03
0.9
1.64
3
1.39
1.2
0.61
Property, plant and equipment
0.13
0.05
0.02
0
0
0.01
0.04
0.03
0.02
0.02
Lease right-of-use assets
0
0.13
0.45
0.37
0.3
0.23
0.14
0.69
Other non-current assets
0.32
0.06
0.02
0.02
0
0.02
0.02
0.02
0.02
0.02
Total assets
1.49
0.41
0.24
1.18
1.35
2.04
3.37
1.67
1.38
1.32
Accounts payable
2.6
3.02
3.01
2.9
2.42
2.36
2.19
1.99
2.09
2.42
Accrued liabilities
2.67
4.16
3.16
3.24
3
1.77
1.25
1.07
1.01
1.17
Deferred revenue
0.1
0.04
0.34
0.51
0.42
0.85
0.19
Short-term debt
1.01
1.09
0.67
0
0.03
0.09
0.02
0
Total current liabilities
9.34
11.8
11
12.4
8.96
5.69
4.87
4.81
6.16
6.64
Long-term debt
0.3
0.34
0
0.02
0.02
0
0
0.05
0.02
Lease liabilities
0
0.03
0.39
0.33
0.25
0.16
0.05
0.65
Total liabilities
10.8
19.8
16.1
18.1
12.2
7.49
6.25
5.48
6.27
7.33
Total debt
7.96
5.07
5.71
0.02
0.02
0.02
0
Paid-in capital
116
117
118
119
123
127
138
141
143
146
Retained earnings
-128
-139
-138
-140
-140
-142
-147
-151
-154
-157
Treasury stock
-0.13
-0.13
-0.13
-0.13
-0.13
-0.13
-0.13
-0.13
-0.13
-0.13
Shareholders' equity
-9.27
-19.4
-15.8
-16.9
-10.9
-5.45
-2.88
-3.81
-4.89
-6.01
Total equity
-9.27
-19.4
-15.8
-16.9
-10.9
-5.45
-2.88
-3.81
-4.9
-6
Total liabilities and equity
1.49
0.41
0.24
1.18
1.35
2.04
3.37
1.67
1.38
1.32
Shares outstanding
0
0.06
0
0
13.1
13.7
48.6
54.1
65.1
86.2
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-3.97
-10.7
1.02
-1.92
-0.28
-2.07
-4.34
-3.49
-2.42
-3.2
Depreciation and amortization
1.22
0.21
0.03
0.02
0
0
0
0.01
0.01
0.01
Stock-based compensation
0.1
0.06
0.04
0.01
0.31
0.23
1.38
1.81
0.12
0.38
Deferred income tax
0
0
0
0
0
0
0
0
0
0
Change in receivables
-0.03
-0.01
-0.01
0
-0.02
-0.02
0.02
-0
0.01
-0.01
Change in inventory
0.35
0.51
0.15
0.07
-0.48
0.03
-0.06
-0.08
-0
0.19
Change in payables
0.78
0.42
-0.01
0.02
-0.37
0.14
0.12
0.04
0.55
1.36
Cash from operations
-1.8
-1.14
-1.37
-0.81
-1.88
-1.59
-1.48
-1.75
-1.12
-1.07
Capital expenditures
0
0
-0
-0.01
-0.03
0
0
-0
Cash from investing
0
0
-0
-0.01
-0.03
0
-0
Debt issued
1.96
0
1.39
1.35
0.52
Debt repaid
-0.22
Stock issued
0.05
1.57
0.04
0
0
0
1.39
0
0.84
0.57
Cash from financing
1.78
1.13
1.36
1.71
1.16
2.07
3.18
0.02
0.92
0.75
Net change in cash
-0.02
-0.01
-0
0.9
-0.72
0.46
1.67
-1.72
-0.2
-0.33
Free cash flow
-1.8
-0.81
-1.88
-1.61
-1.51
-1.75
-1.12
-1.07
Interest paid
0
0.05
0.12
0.01
0.3
0.56
0.15
0.11
0.05
0.06
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.18 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
75.7%
Gross profit / revenue.
Operating margin
-303.8%
Operating income / revenue.
EBITDA margin
-302.5%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-471.5%
Pre-tax income / revenue.
Net margin
-471.2%
Net income / revenue.
Operating cash flow margin
-231.4%
Cash from operations / revenue.
Return on assets (ROA)
-256.3%
Net income / average total assets.
R&D / revenue
52.6%
Research and development expense / revenue.
Stock-based pay / revenue
19.4%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
1.4%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
10,857.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
289.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
49.7%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
28,450.0%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 5y
31.9%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-3.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-26.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-0.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
36.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
34.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
492.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.09x
Current assets / current liabilities.
Quick ratio
0.00x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.00x
(Cash + short-term investments) / current liabilities.
Debt / assets
4.4%
Total debt / total assets.
Liabilities / assets
582.3%
Total liabilities / total assets.
Net debt
$41.0K
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.03
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.01
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.02
Cash from operations / diluted weighted shares.
Book value per share
-$0.06
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
26.7x
Market cap / revenue.
EV/Sales
26.8x
Enterprise value / revenue.
Earnings yield
-17.6%
Net income / market cap (the inverse of P/E).
What was GUIDED THERAPEUTICS INC's revenue in fiscal 2025?
GUIDED THERAPEUTICS INC reported revenue of $767.0K for fiscal 2025, 10,857.1% higher than the year before.
Was GUIDED THERAPEUTICS INC profitable in fiscal 2025?
No. It reported a net loss of $3.2M.
How much free cash flow did GUIDED THERAPEUTICS INC generate in fiscal 2025?
Cash from operations of $1.1M minus capital expenditures of $2.0K left free cash flow of -$1.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.